Literature DB >> 11256512

Beneficial clinical effects of ozonated autohemotherapy in chronically dialysed patients with atherosclerotic ischemia of the lower limbs--pilot study.

L Tylicki1, T Niew głowski, B Biedunkiewicz, S Burakowski, B Rutkowski.   

Abstract

Ozonated autohemotherapy is a controversial but successful method of treatment, used in particular in European countries. There are many fields in which medical ozone could be of value: treating different infections, immunodeficiency syndromes, neoplasms. Encouraging results have also been achieved in the treatment of atherosclerotic ischemia of the lower limbs. In this preliminary study, the influence of blood ozonation on the intensity of symptoms of ischemia of the lower extremities was analysed among dialysed patients with chronic renal failure. We examined 5 hemodialyzed patients and 7 patients treated with peritoneal dialysis immediately before and after 14 sessions of ozonated autohaemotherapy. Eleven patients (91.6%) reported a subjective decrease in perceived intensity of ischemic pains, or observed prolongation of intermittent claudication distance. During march tests performed on a treadmill, we found significant prolongation of intermittent claudication distance in all examined patients - 65.6% (mean value, p (< or =0.01). Patients treated with peritoneal dialysis achieved much greater improvement than did hemodialyzed patients (165% vs. 42%). We concluded that autohemotherapy with ozone, in a concentration of 34.4 mcg/ml of blood, is safe, easily applied and may be useful In the therapy of atherosclerotic ischemia of lower extremities among dialyzed patients. It could also be a complement to current treatment, especially in cases where the latter has failed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11256512

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  7 in total

1.  Ozonized autohemotransfusion does not affect arterial vasodilation in patients with peripheral arterial disease.

Authors:  Antonino Coppola; Ludovico Coppola; Carlo Luongo; Alessandro Arciello; Federico Cacciapuoti; Diana Lama; Margherita Luongo; Luigi Ruggiero; Agostino Pastore; Giorgio Gombos
Journal:  Int J Angiol       Date:  2007

2.  Ozonated autohemotherapy elevates PPAR-γ expression in CD4+ T cells and serum HDL-C levels, a potential immunomodulatory mechanism for treatment of psoriasis.

Authors:  Jinrong Zeng; Zhen Tang; Yuezhong Zhang; Xiaoliang Tong; Jianhua Dou; Lihua Gao; Shu Ding; Jianyun Lu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

3.  Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study.

Authors:  Emma Borrelli; Angelica Diadori; Alessandro Zalaffi; Velio Bocci
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

Review 4.  Expert consensus of Chinese Association for the Study of Pain on the application of ozone therapy in pain medicine.

Authors:  Zhi-Gang Zhuang; Li-Juan Lu; Bao-Gan Peng; Ke Ma; Zhen-Yu Cai; Zhi-Jian Fu; Guang-Zhao Liu; Jin-Feng Liu; Wen-Tao Liu; Xiao-Hong Li; Tao Song; Da-Sheng Wu; Jing Yao; Peng Yao; Jian-She Yu; Yan-Qing Liu
Journal:  World J Clin Cases       Date:  2021-03-26       Impact factor: 1.337

Review 5.  Ozone as Janus: this controversial gas can be either toxic or medically useful.

Authors:  Velio Bocci
Journal:  Mediators Inflamm       Date:  2004-02       Impact factor: 4.711

6.  Major ozonated autohemotherapy promotes the recovery of upper limb motor function in patients with acute cerebral infarction.

Authors:  Xiaona Wu; Zhensheng Li; Xiaoyan Liu; Haiyan Peng; Yongjun Huang; Gaoquan Luo; Kairun Peng
Journal:  Neural Regen Res       Date:  2013-02-15       Impact factor: 5.135

7.  The Relationship between Ozone and Human Blood in the Course of a Well-Controlled, Mild, and Transitory Oxidative Eustress.

Authors:  Gerardo Tricarico; Valter Travagli
Journal:  Antioxidants (Basel)       Date:  2021-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.